TY - JOUR
T1 - 3-D OCT angiographic evidence of Anti-VEGF therapeutic effects on retinal capillary hemangioma
AU - Otero-Marquez, Oscar
AU - Chui, Toco YP
AU - Pinhas, Alexander
AU - Castanos Toral, Maria V.
AU - Zhou, Davis B.
AU - Migacz, Justin
AU - Rosen, Richard B.
N1 - Publisher Copyright:
© 2022
PY - 2022/3
Y1 - 2022/3
N2 - Purpose: To report the impact of intravitreal anti–vascular endothelial growth factor (VEGF) therapy on a retinal capillary hemangioma (RCH) using clinical OCT angiography (OCT-A) in addition to standard imaging modalities. Observations: A 25-year-old male patient with Von Hippel-Lindau (VHL) disease presented with a history of bilateral RCH. No view was present in the right eye. Examination of the left eye revealed six peripheral RCH, the smallest of which was temporal to the macula with active exudation. This RCH was thought to be the source of cystoid macular edema (CME) involving the fovea, and therefore, the source of vision decline. 11 injections of 1.25mg of Bevacizumab EA across 14-month was given. Comparison of the pre- and post-treatment OCT-A at the temporal RCH showed a reduction of CME and regression of RCH. Conclusion: Anti-VEGF therapy appeared to stabilize the visual acuity and produce partial regression of RCH. It offers a safe option when visual acuity is threatened. OCT and OCT-A have the ability to document the impact of antiangiogenic therapy on RCH. 3D renderings of OCT-A offer enhanced sensitivity to recognition of structural and functional changes of RCH which may prove useful for monitoring treatment response.
AB - Purpose: To report the impact of intravitreal anti–vascular endothelial growth factor (VEGF) therapy on a retinal capillary hemangioma (RCH) using clinical OCT angiography (OCT-A) in addition to standard imaging modalities. Observations: A 25-year-old male patient with Von Hippel-Lindau (VHL) disease presented with a history of bilateral RCH. No view was present in the right eye. Examination of the left eye revealed six peripheral RCH, the smallest of which was temporal to the macula with active exudation. This RCH was thought to be the source of cystoid macular edema (CME) involving the fovea, and therefore, the source of vision decline. 11 injections of 1.25mg of Bevacizumab EA across 14-month was given. Comparison of the pre- and post-treatment OCT-A at the temporal RCH showed a reduction of CME and regression of RCH. Conclusion: Anti-VEGF therapy appeared to stabilize the visual acuity and produce partial regression of RCH. It offers a safe option when visual acuity is threatened. OCT and OCT-A have the ability to document the impact of antiangiogenic therapy on RCH. 3D renderings of OCT-A offer enhanced sensitivity to recognition of structural and functional changes of RCH which may prove useful for monitoring treatment response.
KW - Anti-VEGF
KW - Optical coherence tomography angiography
KW - Retinal capillary hemangioma
KW - Von Hippel-Lindau disease
UR - http://www.scopus.com/inward/record.url?scp=85124224345&partnerID=8YFLogxK
U2 - 10.1016/j.ajoc.2022.101394
DO - 10.1016/j.ajoc.2022.101394
M3 - Article
AN - SCOPUS:85124224345
SN - 2451-9936
VL - 25
JO - American Journal of Ophthalmology Case Reports
JF - American Journal of Ophthalmology Case Reports
M1 - 101394
ER -